<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="209785">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356642</url>
  </required_header>
  <id_info>
    <org_study_id>TPD102031</org_study_id>
    <nct_id>NCT00356642</nct_id>
  </id_info>
  <brief_title>Study Of Single And Ten Day Repeat Atopical Applications Of GW842470X Cream On The Skin Of Patients With Atopic Dermatitis</brief_title>
  <official_title>A Randomised, Single-Blind, Dose-Rising Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Ten Day Repeat Topical Applications of GW842470X Cream on the Skin of Patients With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study of this study is to investigate the safety, tolerability and
      pharmacokinetics of GW842470X in patients with atopic dermatitis. GW842470X is an inhibitor
      of phosphodiesterase 4 (PDE4).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical examination</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead ECG</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Lead II cardiac monitoring</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical lab tests</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to max concentration and terminal half-life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCORAD</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BSA determination</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical photography</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of barrier function using trans-epidermal water loss (TEWL)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin biopsy (biomarkers CD4+, CD8+, eosinophils, total IgE)</measure>
  </secondary_outcome>
  <enrollment>42</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Dermatitis, Atopic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW842470X</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Atopic dermatitis patients (moderate to severe) who are otherwise healthy.

          -  BMI range 18.5-29.9m2 at least 2 index lesions and BSA involvement &gt;10%.

          -  14 day washout of current therapy.

        Exclusion criteria:

          -  Patients who have had systemic treatment for atopic dermatitis or other topical or
             transdermal treatments (such as nicotine, hormone replacement therapies) within 14
             days prior to first application of study medication and/or topical treatment with tar
             or any treatment with corticosteroids within 14 days prior to first application
             except 1% hydrocortisone.

          -  Patients must not present with any systemic disorders or active skin disease other
             than atopic dermatitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>67 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>May 31, 2012</lastchanged_date>
  <firstreceived_date>July 25, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PK</keyword>
  <keyword>GW842470X</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>PD</keyword>
  <keyword>Atopic Dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
